Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | GUCY1A1 | Q02108 | 8/20 | 0.51 |
| ▸ | GUCY1B1 | Q02153 | 8/20 | 0.51 |
| ▸ | PDE5A | O76074 | 10/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL255841 | 0.93 | ADORA3 (0.63) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL10064748 | 0.92 | ADORA3 (0.62) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL5472954 | 0.91 | ADORA3 (0.67) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL248358 | 0.90 | ADORA3 (0.73) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL29379641 | 0.90 | ADORA3 (0.73) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL10064372 | 0.89 | ADORA3 (0.63) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL10064296 | 0.89 | ADORA3 (0.63) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL12630446 | 0.89 | ADORA3 (0.67) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Hydrochloric Acid SCHEMBL28612648 | 0.89 | ADORA3 (0.72) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL5481770 | 0.89 | ADORA3 (0.64) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012010576-A1 | CARBAMATE-SUBSTITUTED DIAMINOPYRIMIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-26 | — | — | WO | disclosed |